HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.

Heilongjiang ZBD Pharmaceutical Co., Ltd.

603567

CNE100002219

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 14/01/2025			5-day change	1st Jan Change
11.05 ^CNY	+3.27%		-5.31%	-4.74%

12:27pm	Heilongjiang ZBD Pharmaceutical Unit Gets China Approval for Hypertension Drug	MT
12-17	Heilongjiang ZBD Pharmaceutical Secures Approval for Chemical Raw Material Drug Listing	MT

ZBD Pharma Gets China Approval for Antibacterial Injection

December 03, 2024 at 08:00 am

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Heilongjiang ZBD Pharmaceutical Co., Ltd.

Heilongjiang ZBD Pharmaceutical Unit Gets China Approval for Hypertension Drug	11:27am	MT
Heilongjiang ZBD Pharmaceutical Secures Approval for Chemical Raw Material Drug Listing	12-17	MT
ZBD Pharma Gets China Approval for Antibacterial Injection	12-03	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	29/10/24	CI
China Rejects ZBD Pharmaceutical's Application For Skin Infection Drug	27/08/24	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	26/08/24	CI
ZBD Pharmaceutical Gets Nod to Market Bromhexine Hydrochloride Injection	19/07/24	MT
ZBD Pharmaceutical Gets Nod to Trial Qingjianghewei Granules	11/07/24	MT
ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets	27/05/24	MT
China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable	07/05/24	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04/24	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04/24	CI
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets	21/02/24	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug	26/09/23	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index	18/09/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to FTSE All-World Index	18/09/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	10/05/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 10, 2022 has closed with 2,560,300 shares, representing 0.27% for CNY 30 million.	09/05/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	28/04/23	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	04/04/23	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	03/01/23	CI
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies	06/12/22	MT

Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.

Duration

Period

Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.

603567: Dynamic Chart

HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.

Employees

2,545

Sector

Pharmaceuticals

Calendar

24/04/2025 - Q1 2025 Earnings Release (Projected)

More about the company